How do GLP-1 drugs actually reduce cravings?
GLP-1 drugs work by mimicking a natural hormone that regulates appetite and blood sugar, but they also directly affect the brain's reward system. These medications activate receptors in areas of the brain that control pleasure and motivation—the same circuits that drive cravings for alcohol, nicotine, and hyper-palatable foods [4]. By dampening the reward signal, they make drinking or overeating less appealing.
A 2025 meta-analysis of three studies involving 431 patients found that GLP-1 agonists significantly reduced alcohol cravings (standardized mean difference -0.97, a large effect) and cut the number of heavy drinking episodes by about 31% [1]. Another study analyzed over 68,000 social media posts and found that 71% of alcohol-related comments described reduced desire to drink or fewer cravings [2]. This suggests the effect is noticeable enough that people talk about it spontaneously.
What does the evidence show for alcohol specifically?
The strongest evidence comes from a 2025 meta-analysis that pooled data from 431 patients across three clinical trials. It found that GLP-1 drugs not only reduced cravings but also lowered scores on the Alcohol Use Disorders Identification Test (AUDIT) by an average of 4.3 points—a clinically meaningful drop [1]. A separate 2023 study of 153 people with obesity who were current drinkers found that those taking semaglutide or tirzepatide reported significantly fewer drinks per drinking episode and lower odds of binge drinking compared to before starting the medication [2].
A 9-week randomized controlled trial specifically testing semaglutide in adults with alcohol use disorder found that weekly doses reduced alcohol craving compared to placebo, and improved some drinking outcomes [5]. However, a 26-week trial using an older GLP-1 drug (exenatide) did not find a significant reduction in drinking compared to placebo, suggesting that newer drugs like semaglutide may be more effective [4]. Overall, the evidence is promising but still early—most studies are small, and long-term effects are not yet known.
Does this work for addictive foods too?
The evidence for food cravings is less direct but biologically plausible. GLP-1 drugs are already FDA-approved for weight management, and they reduce overall calorie intake by slowing stomach emptying and enhancing feelings of fullness [4]. But beyond that, they target the same brain reward pathways that drive compulsive eating of high-sugar, high-fat foods.
A 2024 systematic review of clinical trials found that GLP-1 drugs reduced substance use (alcohol and nicotine) in 3 out of 5 studies, and also led to significant weight loss and lower BMI [3]. While no study in this set specifically measured 'addictive food' cravings, the overlap in brain mechanisms—and the fact that these drugs reduce consumption of rewarding substances broadly—suggests they likely help with food addiction as well. One expert review notes that the dual effect on cravings and weight loss makes these drugs particularly appealing for people who struggle with both alcohol and overeating [4].
What are the caveats and unknowns?
Despite the excitement, the research is still in early stages. Most studies are small, short-term (9–26 weeks), and often funded by drug manufacturers. A 2026 expert review warns that we don't yet know whether the benefits last after stopping the medication, or whether people with alcohol use disorder will adhere to treatment as well as those taking it for diabetes [4].
Additionally, not all GLP-1 drugs work equally well. An older drug, exenatide, failed to show a significant effect on drinking in a 26-week trial, while newer drugs like semaglutide and tirzepatide have shown stronger results [4]. Side effects like nausea and vomiting are common, especially when starting the medication, and may limit use for some people. Finally, no study here directly tested effects on 'addictive foods' as a primary outcome—so while the logic is strong, the proof is not yet definitive.
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2023 to 2026, 4 from 2024 or later, 3 in Q1 journals, collectively cited 152 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 57 papers retrieved from a database of over 500 million.
Sources used in this answer
SUN-576 Glucagon-like Peptide-1 (GLP-1) Receptor Agonists For Alcohol Use Disorder: a Systematic Review and Meta-analysis
A meta-analysis of 431 patients found GLP-1 agonists significantly reduced alcohol cravings (large effect, SMD -0.97), heavy drinking episodes (31% reduction), and AUDIT scores (4.3-point drop) [1].
Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
A study of 153 people with obesity found that those taking semaglutide or tirzepatide reported significantly lower alcohol intake, fewer drinks per episode, and reduced binge drinking odds compared to before medication and to a control group [2].
Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials
A systematic review of 5 clinical trials (630 participants) found that GLP-1 drugs reduced substance use (alcohol and nicotine) in 3 of the 5 studies, and also led to weight loss and lower BMI [3].
Glucagon‐like peptide‐1 receptor agonists in alcohol use disorder: Multi‐system effects, early clinical promise and uncertain long‐term use
An expert review highlights that GLP-1 drugs modulate both central reward pathways and peripheral metabolism, but notes that long-term efficacy, optimal dosing, and effects after discontinuation remain unknown [4].
Weekly semaglutide reduces craving in adults with alcohol use disorder
A 9-week randomized trial found that weekly semaglutide reduced alcohol craving compared to placebo in adults with alcohol use disorder, and improved some drinking outcomes [5].